Jean Combalbert is the CEO of Ogeda which he joined in April 2006, with more than 20 years of experience in pharmaceutical and biotech companies. Dr Combalbert received his PhD in pahramcy from the University of Marseille, France. Following post-doctoral research on pharmacokinetics and metabolism at the French public research institute, INSERM, he joined the pharmaceutical industry where he held senior positions at Sanofi then with Galderma in France and USA. Prior to joining Ogeda, he was Vice-President Pharmaceutical Development at Proteus SA, Nimes, France, then Chairman & CEO of Entomed SA, Strasbourg, France.
Before founding Bioxodes, Edmond Godfroid was a long standing senior professor at the University of Brussels (ULB) where he applied his expertise in molecular biology to the discovery of pharmacologically active proteins in the saliva of the Ixodes tick. Dr Godfroid’s and his former team’s work is the basis for the creation of Bioxodes. He received his PhD in Molecular Biology from ULB in 1988 and subsequently acquired post-doctoral experience in the field of Alzheimer’s disease at the Université Catholique de Louvain (UCL). In 1992, he joined Applied Genetics (ULB) where he developed the first PCR-based diagnostic device specific to the tick-borne bacterial pathogen, Borrelia burgdorferi, the causal agent of Lyme disease. In 1995, Dr Godfroid began research on the molecular interaction between Ixodes ticks and their hosts. Until recently he was the Head of the Ectoparasite Molecular Biology Unit at ULB. He has experience of a range of collaborations with academic groups and pharmaceutical companies. Professor Godfroid is a co-founder of Bioxodes.
Pierre Detrixhe is Investment Manager at “Groupe Capital & Croissance”. He manages a fund (“Financière Spin-off Luxembourgeoise”) providing early-stage financings to technological start-ups. Prior to that, he worked as technology transfer officer and scientist in the area of biotechnology. He holds a master in bioengineering and a master in Management.
Chris Buyse is the former Chief Financial Officer of Thrombogenics NV and has more than 20 years’ experience in international company finance, including running and establishing best financial practice. Before ThromboGenics, as CFO of the Belgian biotechnology company CropDesign, he coordinated its acquisition by BASF in early 2007. Mr Buyse has also been Finance Director of WorldCom/MCI Belux, a European subsidiary of one of the world’s largest telecom companies, and CFO and interim CEO of Keyware Technologies. He has also held financial positions at Spector Photo Group, Suez Lyonnaise des Eaux and Unilever.
Eric Halioua is President and CEO of PDC*line Pharma. He is as well Board member of the biotechnology company VitriCell, HairClone and Innobiochips. He has raised nearly €80 million over the course of his career and has had numerous successes in the sale and initial public offering of biotechnology companies. He is co-Inventor of the first GMP approved mobile manufacturing unit for cell therapy. Eric is co-founder of four biotechnology called Myosix, Murigenetics, HairClone and Digital Orthopaedics. He was as well principal of the life sciences practice of Arthur D. Little in Paris and Boston during 11 years. He holds two master degrees in Pharmacology and Molecular Biology and a MBA from ESSEC Business School (Paris).
With his Civil Engineer degree at the KU Leuven, Hervé de Radiguès started his professional activities in the chemical industries. After a few years, he chose to become an industrial entrepreneur by acquiring and developing different companies in the plastic injection sector. In 2002, reorienting his activities, he launched companies specialized in the distribution of technical parts for the Telecom, Electricity and Gas industries. He studied the new bio-medical applications and has invested in some companies specialized in this sector.
François Fontaine holds a law degree from the University of Brussels and he is a specialist in Tax affairs. He was counsel in various public institutions and cabinet. He is currently general counsel to the Federal Holding and Investment Company (SFPI)-FPIM. SFPI is focusing its investments on innovative Belgian Companies, hoping to contribute to their financial and societal success story. Mr. Fontaine is also Board member of several companies including biotechs.
Michel Guyaux has more than 20 years of experience in pharmaceutical research. He was latterly Senior Group Leader at the multinational biopharmaceutical firm UCB where he focused on drug discovery research and development in the field of cardiovascular, inflammatory and CNS diseases. As project manager and head of safety pharmacology department, he was actively involved in the preclinical evaluation and development programs of new therapeutical entities including small and large molecules. He is a specialist in early stage clinical and pre-clinical programs integrating toxicology, pharmacokinetics and pharmacodynamics. He obtained his PhD in chemistry from the University of Brussels (ULB) and a Master in pharmacochemistry and drug design from the University of Lille. He joined the pharmaceutical sector after postdoctoral research in oncology and parasitology in the University of California (San Francisco) and the University of Brussels (ULB), respectively. Dr Guyaux is a co-founder of Bioxodes.
Joëlle Thonnard graduated as Medical Doctor at the Université de Liège (ULiège). She specialized in Clinical Biology in parallel to completing a DES in Molecular Biology at the Université Catholique de Louvain (UCL). This let her to became a researcher in cancer immunology at the Institute of Cellular Pathology in Brussels. Then she joined the pharmaceutical industry. She started at the head quarter of GSK Biologicals in Belgium, the vaccine branch of GSK, first in R&D as Technology Group Head Bioinformatics, then in clinical development as Safety Physician. Thereafter she took over a local role in Belgium as Medical Affairs Manager at Celgene active in onco-haematology; in parallel, she completed a post-graduate in Business Management at the Katholiek Universiteit of Leuven (KUL). Then she became Director Medical and Clinical affairs at Promethera, a biotech company developing new liver cell-based therapies for orphan genetic diseases as well as inflammatory liver diseases. After this experience, she joined Bioxodes as Clinical Director.
Joël Tassignon obtained his PhD in immunology from the University of Brussels (ULB) and a Master in Total Quality Management from the Polytechnic Faculty of the University of Mons. After postdoctoral research on breast cancer at Bordet Institute (Brussels) and on transplantation at Erasme Hospital (ULB, discovery of a new immune-suppressor), he became project manager and lab director of a spin-off from the ULB. He then continued working in the management field as coach in innovation for companies and as director of a laboratory in a Belgian research center acting as a CRO. In parallel to the management of people, projects, technological platforms and laboratories, he was also involved in the management of several types of quality systems as manager and auditor.